



\$~61

* **IN THE HIGH COURT OF DELHI AT NEW DELHI**

+ CS(COMM) 294/2026, I.A. 7603/2026, I.A. 7604/2026, I.A. 7605/2026, I.A. 7606/2026, I.A. 7607/2026, I.A. 7608/2026, I.A. 7609/2026, I.A. 7610/2026 & I.A. 7611/2026,

NOVO NORDISK A/S & ANR.

.....Plaintiffs

Through: Dr. Abhishekh Manu Singhvi and Mr. Amit Sibal, Senior Advocates alongwith Mr. Hemant Singh, Ms. Mamta Jha, Mr. Rishabh Paliwal, Mr. Shreyansh Gupta, Mr. Sanchit Sharma, Mr. Saksham Dhingra, Ms. Smriti Nair, Mr. Ankit Handa and Mr. Amit Bhandari, Advocates.

versus

DR. REDDY'S LABORATORIES LIMITED

.....Defendant

Through: Mr. Dayan Krishan and Mr. J. Sai Deepak, Senior Advocates alongwith Mr. Sidhant Goel, Mr. Mohit Goel, Mr. Aditya Goel, Mr. Deepankar Mishra and Mr. Kartikeya Tandon, Advocates.

CORAM:

HON'BLE MR. JUSTICE TUSHAR RAO GEDELA

ORDER

%

24.03.2026

I.A. 7605/2026(Additional Documents)

1. The present application has been filed on behalf of the plaintiffs under Order XI Rule 1(4) of the Code of Civil Procedure, 1908 (hereinafter referred to as 'CPC') as applicable to commercial suits under the Commercial Courts Act, 2015 (hereinafter referred to as 'CC Act') seeking leave to place on record additional documents.

2. The plaintiffs are permitted to file additional documents in accordance with the provisions of the CC Act and the Delhi High Court (Original Side)



Rules, 2018.

3. Accordingly, the application stands disposed of.

I.A. 7604/2026 (Pre-Institution Mediation)

4. This is an application filed by the plaintiffs seeking exemption from instituting pre-litigation Mediation under Section 12A of the CC Act.

5. As the present matter contemplates urgent interim relief, in light of the judgment of the Supreme Court in *Yamini Manohar vs. T.K.D. Keerthi: (2024) 5 SCC 815*, exemption from the requirement of pre-institution Mediation is granted.

6. The application stands disposed of.

I.A. 7606/2026 (Exemption)

7. This is an application filed on behalf of the plaintiffs under Section 151 of CPC seeking exemption from filing clearer/dim/illegible documents along with the captioned suit.

8. Exemption allowed, subject to just exceptions. However, true typed/translated/clear copies of the documents with proper margins be filed within two weeks with an advance copy to the defendant.

9. The application stands disposed of.

I.A. 7607/2026(seeking administration of interrogatories)

10. This application has been filed by the plaintiffs under Order XI Rules 2 and 5 of the CPC as amended by the CC Act read with Section 151 of CPC, seeking administration of interrogatories and production of the documents alongwith supporting affidavit.

11. Issue Notice.

12. Mr. Mr. Sidhant Goel, learned counsel accepts notice on behalf of the defendant.

13. Let the reply to the application be filed within a period of four weeks from date. Rejoinder thereto, if any, be filed within a period of two weeks



thereafter.

14. List before the Joint Registrar on 22.05.2026 for completion of service and pleadings.

15. List before this Court on 24.04.2026.

I.A. 7608/2026 (Seeking Additional time to file Court fees)

15. The present application has been filed by the plaintiffs under Section 149 read with Section 151 of CPC, seeking exemption from payment of Court Fees at the time of the filing of the suit.

16. Considering the submissions made in the present application, an extension of two weeks is granted to affix the requisite court fees.

17. The application stands disposed of.

I.A. 7609/2026 (Exemption)

18. This is an application filed on behalf of the plaintiffs under Section 151 of CPC seeking exemption from filing notarized affidavit under Section 63(4)(C) of the Bharatiya Sakshya Adhiniyam, 2023 alongwith supporting affidavit.

19. Exemption is allowed, subject to just exceptions. The notarized affidavit under Section 63(4)(C) of the Bharatiya Sakshya Adhiniyam, 2023 alongwith supporting affidavit be filed within four weeks with an advance copy to the defendants.

20. The application stands disposed of.

I.A. 7610/2026 (Appointment of Local Commissioner)

21. The present application has been filed by the plaintiffs under Order XXVI Rule 9 read with Order XXXIX Rule 7 of CPC seeking appointment of Local Commissioners.

22. In the view of the submission in the affidavit and agreement between the parties under the I.A. 7603/2026, this application has been rendered infructuous.



23. The application stands disposed of as infructuous.

I.A. 7611/2026 (Exemption)

24. This is an application filed on behalf of the plaintiffs under Section 151 of CPC seeking liberty/exemption from dividing the documents in Part-IV in Volumes alongwith supporting affidavit.

25. Exemption is allowed.

26. The application stands disposed of.

I.A. 7603/2026 (Under Order XXXIX Rules 1 and 2 of the CPC)

27. Present application has been filed on behalf of the plaintiffs under Order XXXIX Rules 1 & 2 of CPC, seeking *ex-parte ad-interim* injunction against the defendant.

28. Arguments of Dr. Abhishekh Manu Singhvi, Mr. Amit Sibal, learned senior counsel for plaintiffs and Mr. Dayan Krishnan and Mr. J. Sai Deepak, learned senior counsel for the defendant have been heard.

29. After some arguments, Mr. Dayan Krishnan and Mr. J. Sai Deepak, learned senior counsel for the defendant have handed over two affidavits, one of which is furnished by Dr. B. Dinesh Kumar, head, Intellectual Property Management, IPDO of defendant and other by Dr. Venkat Ramana Naidu, Global Head Research & Development (R&D)- Orals, Topicals & Nasals in the defendant company. The said affidavits are extracted hereunder:-

“AFFIDAVIT

I, Dr. B. Dinesh Kumar, aged about 53 years, son of Shri Bala Raju Bezawada, employed for gain at 8-2-337, Road No.3, Banjara Hills, Hyderabad - 500034, presently at Hyderabad, Telangana, do hereby solemnly affirm and declare as under:

- 1. That I am the Head, Intellectual Property Management, IPDO of Defendant and am fully authorized and competent to sign and depose this Affidavit on behalf of Defendant.*



2. *That I state that, in relation to Dr. Reddy's Oral Semaglutide Tablets (3 mg, 7 mg and 14 mg), the Defendant company has obtained Clinical Trial No Objection Certificate (CT NOC) vide File No. BIO/CT/24/000142 and conducted clinical trial registered in Clinical Trial Registry of India under CTRI/2025/06/088110. Further, Dr. Reddy's have filed manufacturing and marketing Application No. BIO/CT21/FF/2025/52117 before the Central Drugs Standard Control Organization CDSCO.*
3. *That I state that Indian Patent No. IN 325669 claims a solid oral composition comprising semaglutide in the range of 0.01 mg to 100 mg in combination with a salt of N-(8-(2-hydroxybenzoyl)amino) caprylate, "SNAC", in the range of 0.6 to 2.1 mmol.*
4. *That I state that Dr. Reddy's Oral Semaglutide Tablets do not infringe Indian Patent No. IN 325669, in as much as they contain approximately 0.398 mmol (\approx 120 mg) of SNAC, which falls way outside the claimed range of 0.65 to 2.1 mmol.*
5. *That, by way of this Affidavit, the Defendant affirms and undertakes that, during the subsistence of Indian Patent No. IN325669, the Defendant shall not commercially manufacture or sell Dr. Reddy's Oral Semaglutide Tablets (3 mg, 7 mg and 14 mg) containing SNAC in an amount within the range of 0.6 to 2.1 mmol for India.*
6. *That I further state that the Defendant reserves the right to use the invention covered by IN 325669 solely for activities under Section 107A of the Patents Act, 1970 (the Bolar exemption).*

Sd/-
DEPONENT

Verification

I, the above-named deponent, do hereby verify that the contents of my foregoing affidavit are true and correct to my knowledge. No part of it is false and nothing material has been concealed therefrom.

Verified at Hyderabad, Telangana, on this 21st day of March, 2026

Sd/-
DEPONENT"



“Affidavit on behalf of Authorised Representative of Defendant

I, Dr. Venkat Ramana Naidu, aged 51 years, working a global Head Research & Development (R&D) –Orals, Topicals & Nasals in the Defendant Company, having its registered office at Dr. Reddy’s Laboratories Limited, 8-2-337, Banjara Hills Road No.3, SBI Executive Enclave, Green Valley, Banjara Hills, Hyderabad, Telangana – 500034, do hereby solemnly affirm and state as under:

1. That I am a pharmaceutical Research and Development R & D professional with over 24 years of extensive experience in formulation development, analytical development, manufacturing science, and global technology transfer. I have successfully led end-to-end product development, from concept to commercial launch, across regulated markets including the United States, European Union, Japan, India and Rest of the World. I currently supervise the Defendant’s Oral Semaglutide Tablet development programme and am actively involved in its formulation development and commercialization activities.
2. That I state that, in relation to Dr. Reddy’s Oral /Semaglutide Tablets (3 mg, 7 mg and 14 mg), the Defendant Company has obtained Clinical Trial No Objection Certificate (CT NOC) vide File No. BIO/CT/24000142 and conducted clinical trial registered in Clinical Trial Registry of India under CTRI/2025/06/088110. Further, Dr. Reddy’s have filed manufacturing and marketing Application No. BIO/CT21/ff/2025/52117 before the Central Drugs Standard Control Organization CDSCO.
3. That I state that Dr. Reddy’s Oral Semaglutide Tablets (3 mg, 7 mg and 14 mg), do not infringe Indian Patent No. IN 325669, as the said patent claims a solid oral composition semaglutide in the range of 0.01 mg to 100 mg in combination with a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, preferably its sodium salt (sodium N-(8-(2-hydroxybenzoyl)amino) caprylate, “SNAC”), in a strictly defined range of 0.6 to 2.1 mmol.
4. That Dr. Reddy’s Oral Semaglutide Tablets (3 mg, 7 mg and 14 mg) contain only approximately 0.398 mmol (\approx 120 mg) of SNAC, which falls outside the claimed range, and consequently do not fall within the scope of the IN 325669.

Sd/-
DEPONENT

Verification



I, the above-named deponent, do hereby verify that the contents of my foregoing affidavit are true and correct to my knowledge. No part of it is false and nothing material has been concealed therefrom.

Verified at Hyderabad, Telangana, on this 21st day of March, 2026

*Sd/-
DEPONENT*

The copies of the said affidavits are taken on record, however the defendant shall file the said affidavits within seven working days. Copies of the affidavit are handed over to Mr. Amit Sibal, learned senior counsel appearing on behalf of the plaintiffs.

30. Mr. Sibal, learned Senior Counsel for the plaintiffs handed over a note which, if agreed by the defendant, may form part of this order and would satisfy the apprehension of the plaintiffs. Mr. Dayan Krishnan and Mr. J. Sai Deepak, learned senior counsel for the defendant, under instructions, stated that defendant has no objection in making such a statement.

31. After perusing the affidavit and further deliberations, both the parties have agreed to the following directions, as an interim arrangement:-

- (i) The defendant has agreed not to commercially manufacture, sale, supply/export, offer for sale Semaglutide (Oral Tablet), comprising Semaglutide and salt(s) of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC), wherein the amount of said salt(s) of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is in the range of 0.6 - 2.1 mmol; wherein the amount of the GLP-1 agonist Semaglutide is in the range of 0.01 mg to 100 mg as claimed under Claim 1 of the plaintiffs' patent no.IN 325669.
- (ii) Apart from the above, the defendant shall also not breach the range 0.6 to 2.1 mmol claimed under the claim 1 of the plaintiffs' patent



IN325669.

(iii) The defendant assures to handover a sample of 10 strips (each of 3 mg, 7 mg and 14 mg) at cost, under brand names “OBEDA” and “MASHLO” of the finished products with the leaflet including tablets and entire packaging before the date of launch to Ms. Mamta Rani Jha, learned counsel for the plaintiffs.

(iv) The plaintiffs undertake that the Technical Data/Report arrived at and submitted after the aforesaid samples are tested, shall be kept confidential and not be revealed to any person and would be strictly used for the purpose of this Suit.

32. The aforesaid arrangement is without prejudice to rights and contentions of any of the parties.

33. Two weeks’ time is granted to file the reply. Rejoinder thereto, if any, be filed within one week thereafter.

34. List on 24.04.2026.

CS(COMM) 294/2026

35. Let the plaint be registered as a suit.

36. Issue summons.

37. Summons accepted by Mr. Siddhant Goel, learned counsel for the defendant who waives the issuance of summons to the defendant.

38. The Written Statement shall be filed by the defendant within 30 days from the date of the receipt of summons. Alongwith the Written Statement, the defendant shall also file Affidavit of Admission/Denial of the documents of the plaintiffs, without which the Written Statement shall not be taken on record.

39. Liberty is granted to the plaintiffs to file Replication, if any, within 30 days from the receipt of the Written Statement. Along with the Replication filed by the plaintiffs, an Affidavit of Admission/Denial of the documents of defendant be filed by the plaintiffs, without which the Replication shall not be



taken on record.

40. In case any party is placing reliance on a document, which is not in their power and possession, its details and source shall be mentioned in the list of reliance, which shall also be filed with the pleadings.

41. If any of the parties wish to seek inspection of any documents, the same shall be sought and given within the prescribed timelines.

42. List before the Joint Registrar (Judicial) on 26.05.2026 for completion of service and pleadings.

43. List before the Court on 24.04.2026.

TUSHAR RAO GEDELA, J

MARCH 24, 2026

kct